Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Immunoglobulin Therapy for Amyotrophic Lateral Sclerosis (ALSIvig)
jRCTs041190028Completed
- Sponsor
- Japan Blood Products Organization
- Start
- May 2019
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in amyotrophic lateral sclerosis (ALS), sponsored by Japan Blood Products Organization. Primary endpoint: Manual muscle test. Started May 2019; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCTs041190028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190028.